



Provider Bulletin # 18-09 Diagnostic Laboratory Services in Outpatient Drug and Alcohol Clinics Frequently Asked Questions (FAQ)

- 1. When will this change go into effect?**

This change will go into effect September 17, 2018.
- 2. Do the changes in lab screenings apply to urine drug screens (UDS) only, or do they also apply to bloodwork (complete blood counts (CBC), lipids, etc.)?**

The changes apply to all lab screens that are completed to detect/identify and confirm the use of substances.
- 3. Does this change apply to suboxone providers as well?**

This change applies to all Substance Abuse and Mental Health Services Administration (SAMHSA) Opioid Treatment Provider /Narcotic Treatment Provider (OTP/NTP) providers.
- 4. Will rate enhancements include coverage for required confirmations?**

Yes, the rate enhancements will include coverage for *required* confirmations.
- 5. Will CBH notify the labs of these changes?**

Yes, CBH is communicating with the CBH-contracted labs regarding the changes.
- 6. Which labs does CBH contract with?**

CBH contracts with Quest Diagnostics Clinical Labs, Atlantic Diagnostic Labs, and Parkway (Almarc) Clinical Labs.
- 7. Will the rate adjustment go into effect on September 17, 2018 as well?**

Yes. The new rate will be reflected on your schedule A as effective September 17, 2018.
- 8. The Bulletin states that CBH will monitor for compliance. What exactly will CBH be monitoring?**

CBH will be monitoring to ensure that members are continuing to receive the minimal required UDS screens that are clinically indicated.
- 9. How did CBH determine that at minimum there should be 16 UDS per year?**

Based on the average number of UDS administered to members receiving medication-assisted treatment (MAT) in the last year.
- 10. What if a provider completes a UDS and it is determined that the member is not appropriate for the MAT program, and is not induced; will CBH cover the cost of the UDS?**

Yes, CBH will cover the cost of the UDS in this scenario.